Current treatment guidelines for CBF‐AML with t(8;21) do not recognize heterogeneity in these patients, and thus, all t(8;21) AML patients generally receive the same induction and consolidation treatments. This evidence concerns the gene CEBPZ and acute myeloid leukemia.